1. A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils;Bjermer;European Respiratory Journal,2014
2. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study;Bjermer;Chest,2016
3. A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils;Maspero;Annals of Allergy, Asthma and Immunology,2014
4. NCT01270464 A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma clinicaltrials.gov/ct2/show/NCT01270464
5. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results;Bleecker;European Respiratory Journal,2016